Skip to content

SL科学

US · SLBT #3370 按市值排名 上市于 2025
1.53 -0.02 -1.29%
实时 - 追踪5344个代码 - 心跳于95秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 94.38 低于历史水平 第2百分位
5年平均 251.00 · 在Biotechnology中排名第506/513
市盈率 -137.27 高于历史水平 第99百分位
5年平均 -473.07
市销率 385.37 低于历史水平 第2百分位
5年平均 762.79 · 在Biotechnology中排名第323/387

同业对比 Biotechnology

公司 市值 市盈率(TTM) 市净率 股息率
SL科学 (SLBT) 857.96M -139.09 95.63 0.00%
Vertex Pharmaceuticals (VRTX) 126.66B 29.11 6.26 0.00%
Moderna (MRNA) 87.04B -27.32 12.87 0.00%
Regeneron Pharmaceuticals (REGN) 81.41B 19.57 2.57 0.46%
argenx SE (ARGX) 51.51B 31.21 6.12 0.00%
BeiGene (ONC) 41.96B 65.32 8.11 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值1.74 经济护城河Narrow 不确定性Very High

当前股价低于晨星合理价值估算13.8%。

合理价值

SL Science Holding Ltd receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 13% discount to our quantitative fair value estimate of $1.74 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.

经济护城河

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

SL科学 讨论区 0 条评论

发表评论